Impact of Increased Amino Acid Intake on Very Low Birth Weight Infants by Sivamurthy, Siddharthan et al.
Kansas Journal of Medicine 2011                                      Increased Amino Acid Intake 
 
31 
 
Impact of Increased Amino Acid Intake on Very Low Birth Weight Infants 
Siddharthan Sivamurthy, M.D.1, Carolyn R. Ahlers-Schmidt, Ph.D.1,  
Katherine S. Williams, M.Ed.1, Jared Shaw2, Paula Delmore, M.S.N.2, Barry T. Bloom, M.D.1,2 
1University of Kansas School of Medicine-Wichita, Department of Pediatrics 
2Wesley Medical Center, Department of Neonatology 
 
Abstract 
Background.  A consensus has not been reached on whether higher doses of parenteral amino 
acids improve growth in preterm infants without causing adverse side effects.  The objective of 
this study was to evaluate the impact of a more rapid increase in amino acids dosing in very low 
birth weight (VLBW) infants during their first few days of life. 
Methods.  The study design was a 1:1 ratio case matched retrospective analysis of data from two 
distinct periods when the hyperalimentation practice differed.  During phase I, a five-day 
incremental dose of amino acids was utilized.  In phase II, a two-step dose increase of amino 
acids was practiced.  Duration of total parenteral nutrition (TPN), weight at 28 days, hepatic and 
renal function tests, and rates of complications were compared.  This study was approved by two 
local IRBs. 
Results. The phase II protocol resulted in an increased dose of amino acid delivered by day 7 (16 
g/k vs 12.8 g/k, p < 0.001). This increased dose of amino acids resulted in a shorter duration of 
TPN usage (16 days vs 18 days, p = 0.001). The increased dosage did not have a detrimental 
effect on hepatic or renal function.  It also did not increase the incidence of feed intolerance or 
bowel perforation.  However, an increase in amino acid dosing did not increase absolute weight 
gain (15 g/k/day vs 13 g/k/day, p = 0.282). 
Conclusions. No unfavorable outcomes were demonstrated with this increased amino acid 
regimen. VLBW infants may be able to tolerate even higher doses in the first month after birth. 
KJM 2011; 4(2):31-36. 
 
 
Introduction 
Considerable research in the area of 
nutrition for preterm infants has resulted in a 
sea change in clinical practice over the last 
several years.  Infants born prematurely miss 
out on an important period of in-utero 
protein accretion.  Multiple etiologies for 
growth failure in the Neonatal Intensive 
Care Unit (NICU) have been recognized and 
one of them is the lack of early 
administration of intravenous amino acids.1 
Evidence suggested this influences growth 
and long term developmental outcomes.2,3 
Most infants between 24 and 29 weeks 
gestation do not achieve the median birth 
weight of the reference fetus of the same 
gestation at the time of discharge.4 For these 
preterm infants to match an intrauterine rate  
 
of growth, it has been postulated that amino 
acid infusion rates as high as 4 g/k/day 
would be required.5 Amino acid supplement-
ation at 3 g/k/day, soon after birth, results in 
a significant decrease in the number of 
infants falling below the 10th percentile for 
weight at 36 weeks corrected gestation and 
shortens time to full enteral feeds.6 This may 
be responsible for improved weight gain. 
Early introduction of amino acids with 
an increase up to a maximum of 3.5 to 4 
g/k/day did not result in a higher incidence 
of adverse effects like hepatic or renal 
dysfunction.7,8 Despite this, fears remain 
about the ability of very low birth weight 
(VLBW)  infants to cope  with high doses of 
amino acids. 
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Increased blood amino acid levels have 
been reported using 3.5 g/k/day when 
compared to 2.5 g/k/day, without the much 
desired improvement in weight gain.9  So, 
does an increased blood amino acid level 
imply toxicity? Amino acid infusions of 3 
g/k/day in neonates weighing less than 1300 
grams resulted in blood profiles of amino 
acids that were equal to or less than those 
seen in 2nd and 3rd trimester fetuses sampled 
by cordocentesis.10 This is supported by an 
earlier observation that enteral intakes 
approximating 3.2 to 3.5 g/k/day more 
closely mimicked intrauterine estimations 
for nitrogen retention.11  Thus, amino acids 
at these doses are likely to be tolerated 
physiologically. 
Historically, amino acids were 
introduced cautiously by increasing the dose 
gradually over several days.  An evidence-
based change in practice was made to 
administer a higher dose of amino acid at an 
earlier time in the first week. This change 
presented an opportunity to compare these 
two distinct periods for weight gain and the 
incidence of adverse events like hepatic and 
renal dysfunction. We hypothesized that this 
newer practice had resulted in an increased 
administration of amino acids, better weight 
gain, and minimal or no adverse effects. 
This investigation sought to replicate the 
findings of previous smaller studies with a 
larger population size.7  
 
Methods 
The phase I practice was to introduce 
intravenous amino acids at 0.5 g/k/day on 
day 1 and increase by 0.5 g/k/day up to a 
maximum of 2.5 g/k/day.  The phase II 
practice was to start on day 0 with 2 g/k/day 
and increase to 3 g/k/day once the total 
intake reaches 100 ml/k/day. Beyond the 
first week, infants were advanced based 
upon individualized decision making to a 
maximum of 3.5 g/k/day in their total 
parenteral nutrition (TPN).  
There is an inherent high degree of 
variability in protein administration. Infants 
in phase II are started at 2 g/k/d and only 
increased to 3 g/k/d when the fluid intake is 
increased to 100 ml/k/d. This increase in 
fluids is dependent on the infant’s 
cardiovascular and respiratory status, hence 
is variable. Consequently, the “desired 
protein intake at 7 days” is not a set amount 
but the most the individual infant is 
clinically able to tolerate. 
The study aim was to compare the two 
groups retrospectively with a convenience 
sample. Infants between the gestational ages 
of 23 and 33 weeks with birth weights 
between 501g and 1500g were selected. 
Infants who were small for gestational age, 
had congenital anomalies, died, or were 
transferred acutely were excluded.  
The two groups were case matched 1:1 
based on same week of gestation at birth and 
within 50g birth weight (see subject 
selection in Figure 1).  The groups were 
compared for differences in weight gain, 
days of total parenteral nutrition (TPN) 
usage, and laboratory evidence of renal and 
hepatic dysfunction.  Laboratory levels more 
than three times in excess of the upper 
reference range were considered clinically 
relevant. The incidence of complications 
like feed intolerance and bowel perforation 
were compared between the two groups. 
This study received approval from two local 
Institutional Review Boards.  
Data analysis.  Comparisons were made 
between the demographic characteristics of 
phase I and phase II subjects to establish 
similarity. Total protein doses at day 7 and 
day 28, duration of enteral feeding, total 
days of TPN, and weight gain at 28 days 
were compared between the two groups. The 
rates of adverse effects, namely hepatic and 
renal dysfunction, as well as feeding 
intolerance and bowel perforation also were 
compared.  The Statistical Package for the 
Social  Sciences  (SPSS)  17.0  was  used for  
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Figure 1.  Characteristics of subject selection.  Abbreviations:   
BW - birth weight, GA - gestational age, SGA - small for  
gestational age. 
 
data analysis. Categorical comparisons were 
made using the chi square test and 
continuous comparisons by the Wilcoxon 
signed rank test. A p value of less than 0.05 
was used to indicate statistical significance.  
 
Results 
Table 1 shows the demographic 
characteristics of the study sample.  There 
were no significant differences between the 
two phases of clinical practice in gestational 
age, birth weight, gender, multiple gestation, 
and ethnicity.  The duration of intravenous 
nutrition was significantly less in phase II 
(16 days vs 18 days, p = 0.001; see Table 2). 
The dose of amino acids received in phase II 
was significantly higher in the first 7 days 
(16 g/k vs 12.8 g/k, p < 0.001). However, 
when measured at 28 days, there was no 
significant difference. 
As shown in Table 3, there was no 
significant increase in the incidence of 
feeding intolerance (20 vs 13, p = 0.201) or 
bowel perforation (0 vs 2, p = 0.499) in 
phase II.  An increase in BUN was noted on 
day 1 in phase II (18 mg/dl vs 14 mg/dl, p < 
0.001; see Table 3). Clinically irrelevant but 
statistically significant increases were noted 
in the day 7 BUN (19 mg/dl vs 18 mg/dl, p 
= 0.022) and creatinine (0.8 mg/dl vs 0.7 
mg/dl, p < 0.001) in phase I.  No significant 
differences in BUN or creatinine levels were 
noted at day 28. There were no significant 
differences in serum bilirubin, AST, ALP 
and GGT between the two groups at day 1, 
day 7, or day 28.  There was no increase in 
the average weight gain noted at 28 days in 
phase II (15 g/k/day vs 13 g/k/day, p = 
0.282).  
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Table 1.  Demographics characteristics.*   
  
Phase I 
 
 Phase II 
 
 
Total number 181 181  
Gestational age in weeks (S.D.) 29 (2) 29 (2)  
Birth weight in kg (S.D.) 1.152 (0.252) 1.156 (0.247)  
Male (percent) 87 (48%) 105 (58%) Χ2(1) = 3.593,  
p = 0.058 
Multiple gestation (percent) 10 (6%) 19 (11%) Χ2(1) = 3.036,  
p = 0.081 
Ethnicity 
White (percent) 133 (73%) 142 (78%) Χ2(3) = 2.139,  
p = 0.544 
 
 
 
Black (percent) 19 (10%) 16 (9%) 
Hispanic (percent) 23 (13%) 16 (9%) 
Other (percent) 5 (3%) 7 (4%) 
Missing (percent) 1 (1%) 0 (0.0%) 
* Χ
2
 = chi square test 
 
Table 2. Differences between Phase I and Phase II.* 
 
Phase I 
 
 Phase II 
 
 
Total protein dose (S.D.) 
1st 7 days in g/kg 
12.8 (6.7) 16 (7.5) w = -4.686, 
p < 0.001 
Total protein dose (S.D.) 
1st 28 days in g/kg 
84 (30) 85 (32.6) w = 0.086,  
p = 0.932 
TPN day count (S.D.) 
 
18 (7) 16 (7) w = -3.347,  
p = 0.001 
Enteral feed day count 
(S.D.) 
21 (5.3) 20 (5.5) w = -0.788,  
p = 0.431 
Weight gain in g/ day 
(S.D.) 
13 (6) 15 (10) w = 1.076,  
p = 0.282 
* w = Wilcoxon signed rank test 
 
Discussion 
The change in protocol was associated 
with an increase in the total dose of protein 
administered by day 7 and a more rapid 
transition to enteral feedings resulting in a 
shorter duration of TPN use.  Enteral intake 
reduces the protein intake given that 
Neosure (22 Kcal/ oz) at 150 ml/k/day 
yields 3 g/k/day of protein. Hence, improved 
enteral tolerance resulted in an earlier 
transition to enteral feeds and resulted in a 
lower total dose of protein at day 28. 
 
As with a previous study, no hepatic 
dysfunction was noted.7 No detrimental 
effects in the form of an increase in the 
incidence of feeding intolerance, bowel 
perforation, or renal dysfunction were noted. 
Contrary to our hypothesis, no clear 
advantage in terms of absolute weight gain 
was noted. This was consistent with one 
previous study.9 In our study, infants were 
not followed to dismissal given the high 
transfer rate out of the practice to other sites  
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Table 3. Adverse effects and laboratory results.* 
 
Phase I 
 
Phase II 
 
 
Feeding Intolerance 
(percent) 
13 (7%) 20 (11%) Χ2(1) = 1.634,  
p = 0.201 
Bowel perforation 
(percent) 
2 (1%) 0 (0%) Χ2(1) = 2.011,  
p = 0.499 
 
Day 1 lab results 
BUN mg/dl (S.D.) 14 (7) 18 (8) w = 5.181, p < 0.001 
Creatinine mg/dl (S.D.) 0.8 (0.3) 0.8 (0.3) w = -1.753, p = 0.080 
Bilirubin mg/dl (S.D.) 0.2 (0.2) 0.2 (0.2) w = -0.222, p = 0.824 
AST U/L (S.D.) 21 (23) 22 (28) w = 0.229, p = 0.819 
ALP U/L (S.D.) 118 (124) 134 (135) w = 1.195, p = 0.232 
GGT U/L (S.D.) 65 (92) 62 (76) w = -0.011, p = 0.992 
 
Day 7 lab results 
BUN mg/dl (S.D.) 19 (10) 18 (12) w = -2.283, p = 0.022 
Creatinine mg/dl (S.D.) 0.8 (0.3) 0.7 (0.3) w = -4.023, p < 0.001 
Bilirubin mg/dl (S.D.) 0.2 (0.2) 0.3 (0.2) w = 0.208, p = 0.835 
AST U/L (S.D.) 17 (15) 16 (14) w = -0.646, p = 0.518 
ALP U/L (S.D.) 213 (197) 210 (188) w = 0.009, p = 0.993 
GGT U/L (S.D.) 59 (94) 45 (52) w = -0.603, p = 0.564 
 
Day 28 lab results 
BUN mg/dl (S.D.) 3 (5) 3 (4) w = 0.604, p = 0.546 
Creatinine mg/dl (S.D.) 0.2 (0.3) 0.2 (0.2) w = -0.940, p = 0.347 
Bilirubin mg/dl (S.D.) 0.2 (1) 0.2 (0.6) w = 0.880, p = 0.379 
AST U/L (S.D.) 9 (16) 10 (18) w = 0.055, p = 0.956 
ALP U/L (S.D.) 172 (264) 171 (241) w = 0.100, p = 0.920 
GGT U/L (S.D.) 26 (55) 33 (64) w = 1.674, p = 0.094 
*w = Wilcoxon signed rank test, Χ2 = Chi square test 
and other care providers. 
A limitation of this study was its 
retrospective design and the inherent 
possibility of failure to capture elements of 
care which might be recognized as 
influential.  In both phases, the total dose of 
amino acids administered at times exceeded 
the maximum amount dictated by the 
protocol. The total dose was left to the 
individual clinician’s discretion. Another 
such  clinical  decision   was   the  timing  of 
transition from intravenous to enteral 
nutrition. These factors might have 
contributed to some variability in the data. 
 
Conclusion 
Given that no unfavorable outcomes 
were demonstrated with the increased amino 
acid regimen, VLBW infants may be able to 
tolerate, and benefit from, even higher doses 
of amino acids in the first month after birth. 
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